Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious, life-threatening rare diseases. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell-based gene therapy approved for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a debilitating genetic skin disorder causing blistering and chronic wounds. The company operates qualified treatment centers in partnership with leading children's hospitals to deliver this therapy. Abeona Therapeutics Inc. advances a pipeline of adeno-associated virus (AAV)-based gene therapies through its AIM vector platform, targeting unmet needs in ophthalmic diseases such as X-linked retinoschisis (ABO-503), Stargardt disease (ABO-504), and autosomal dominant optic atrophy (ABO-505). It also supports partnered programs for Sanfilippo syndrome and other rare neurological conditions. Headquartered in Cleveland, Ohio, and founded in 1974, Abeona Therapeutics Inc. plays a pivotal role in addressing rare genetic disorders with innovative genetic medicines.